COVID-19 Pandemic ‘Significantly’ Affected DCCR Phase 3 Trial, Soleno Says

COVID-19 Pandemic ‘Significantly’ Affected DCCR Phase 3 Trial, Soleno Says

285983

COVID-19 Pandemic ‘Significantly’ Affected DCCR Phase 3 Trial, Soleno Says

The COVID-19 pandemic — which took a heavy toll on people with Prader-Willi syndrome (PWS) and their families, according to a recent webinar — likely influenced the results of the DESTINY PWS Phase 3 trial that was testing the investigational therapy diazoxide choline controlled release (DCCR) at its outbreak. In the webinar, researchers from Soleno Therapeutics, which is developing DCCR, said a new analysis of pre-COVID-19 trial data revealed the therapy’s early results were better…

You must be logged in to read/download the full post.